<sup>18</sup> F-FDG PET/MRI vs MRI in patients with recurrent adenoid cystic carcinoma.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 30548894.
- Also identified by DOI 10.1002/hed.25485.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To evaluate and compare the diagnostic potential of <sup>18</sup> F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging (<sup>18</sup> FDG-PET/MRI) and MRI for recurrence diagnostics after primary therapy in patients with adenoid cystic carcinoma (ACC). A total of 32 dedicated head and neck <sup>18</sup> F-FDG PET/MRI datasets were included in this analysis. MRI and <sup>18</sup> F-FDG PET/MRI datasets were analyzed in separate sessions by two readers for tumor recurrence or metastases. Lesion-based sensitivity, specificity, positive predictive value, negative predictive value and diagnostic accuracy were 96%, 84%, 90%, 93%, and 91% for <sup>18</sup> F-FDG PET/MRI and 77%, 94%, 95%, 73%, and 84% for MRI, resulting in a significantly higher diagnostic accuracy of <sup>18</sup> F-FDG PET/MRI compared to MRI (P < .005). <sup>18</sup> F-FDG PET/MRI is superior to MRI in detecting local recurrence and metastases in patients with ACC of the head and neck. Especially concerning its negative predictive value, <sup>18</sup> F-FDG PET/MRI outperforms MRI.
Medical subject headings
- Carcinoma, Adenoid Cystic
- Head and Neck Neoplasms
- Magnetic Resonance Imaging
- Neoplasm Recurrence, Local
- Positron-Emission Tomography